Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr.

Investors Business Daily

Trump administration at ‘war’ with mRNA technology: scientists alarmed vaccine skeptics could kill research

Public health experts are sounding the alarm over recent move by the NIH to collect information about funding for research into mRNA technology

The Guardian - US

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Are COVID-19 Vaccines Safe and Effective?

Five years after Donald Trump declared a national COVID-19 emergency, here's what the research says.

Reason

Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

MarketBeat

40% Of S&P 500 Stocks Fall Into Dreaded Trump Bear Market

Not sure when President Trump's tariff strategy will push the S&P 500 into a bear market? It's already here for 40% of the S&P 500.

Investors Business Daily

Why Moderna Stock Has Surged 15% This Week Despite Mixed News

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Moderna Stock Slumps 7% On A Surprise Twist In The RFK Jr. Saga

Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding.

Investors Business Daily

Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now?

A promising pipeline provides long-term potential for Moderna.

Barchart

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

MarketBeat

Moderna Stock Reverses As CEO Stephane Bancel Deflects Concerns Over RFK Jr.

Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

Investors Business Daily

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

Barchart

What has the UK Covid inquiry learned so far about vaccines and treatments?

In fourth part of the inquiry, questons were asked about vaccine trials, procurement and the UK’s preparedness for future pandemics

The Guardian - UK

Here's What to Expect From Moderna's Next Earnings Report

Moderna is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit dip.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Fortune

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.

Investors Business Daily

Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines

Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines.

MarketBeat

After a Reset Year, Is Moderna Stock Poised for a Comeback?

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times UK

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna is expediting its cost-cutting program and rolling back R&D amid a drop in vaccination rates and low revenues from a new vaccine.

Investors Business Daily

Is Moderna Stock A Sell After Massive Job Cuts Wrack U.S. Health Agencies?

Moderna stock and other vaccine makers are under pressure after Peter Marks resigned from the FDA. Is MRNA stock a sell?

Investors Business Daily

Moderna Crashes 17%. 'No Inflection In Sight' After Guidance Cut, CMV Shortfall.

Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting initiative.

The Independent UK

Moderna surprises the Street by predicting a bigger-than-expected sales drop

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year

International Business Times

Moderna Stock Poised For Another Drop After Shaving Nearly $1 Billion Off Earnings Estimates

The drug maker's stock plunged more than 17% in pre-market trading after slashing its sales outlook.

Fortune

No norovirus vaccine exists—yet. Moderna says it’s ‘one step closer,’ and you may be eligible to participate in its ongoing clinical trial

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Investors Business Daily

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.